MOLN MOLN
Company Profile ↓Company Overview
MOLN (MOLN) is a publicly traded company listed on with a market capitalization of $167.96M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +13.97% |
| 6 Months: | -8.97% |
| 3 Months: | -5.60% |
| 1 Month: | +4.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.65 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 16.14M | 14.70M | 11.93M | 12.67M | 13.44M |
| Operating Income | -16.14M | -14.70M | -11.93M | -12.67M | -13.44M |
| EBITDA | -16.21M | -19.84M | -11.31M | -12.13M | -12.64M |
| Interest Expense | 5.00K | 4.00K | 3.00K | 6.00K | 7.00K |
| Pretax Income | -16.77M | -20.40M | -11.84M | -12.64M | -13.14M |
| Tax Provision | -2.00K | 0 | 0 | 4.00K | 0 |
| Net Income | -16.77M | -20.40M | -11.84M | -12.65M | -13.14M |
| Diluted EPS | -0.45 | -0.56 | -0.33 | - | -0.35 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 189.56M | 7.04M | 4.97M | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 72.94M | 68.15M | 66.19M | 55.44M |
| Operating Income | - | 116.61M | -61.11M | -61.22M | -55.44M |
| EBITDA | - | 120.85M | -59.53M | -51.65M | -59.49M |
| Interest Expense | - | 605.00K | 34.00K | 25.00K | 18.00K |
| Pretax Income | - | 117.85M | -61.98M | -54.04M | -61.65M |
| Tax Provision | - | 0 | 0 | 2.00K | 2.00K |
| Net Income | - | 117.85M | -61.98M | -54.04M | -61.65M |
| Diluted EPS | - | 3.54 | -1.89 | -1.59 | -1.65 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 262.26M | 198.35M | 158.53M | 102.11M |
| Current Assets | - | 254.75M | 192.46M | 154.28M | 96.88M |
| Cash & Equivalents | - | 87.95M | 67.31M | 63.87M | 82.65M |
| Inventory | - | - | - | - | - |
| Receivables | - | 521.00K | 295.00K | 286.00K | 253.00K |
| Total Liabilities | - | 27.09M | 21.92M | 16.89M | 21.77M |
| Current Liabilities | - | 17.25M | 14.42M | 10.79M | 11.03M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 4.85M | 3.65M | 2.44M | 3.64M |
| Total Equity | - | 235.17M | 176.43M | 141.64M | 80.33M |
| Shares Outstanding | - | 36.04M | 36.35M | 40.36M | 40.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 118.57M | -59.01M | -59.25M | -51.26M |
| Investing Cash Flow | - | -101.12M | 44.64M | 40.49M | 72.55M |
| Financing Cash Flow | - | -1.57M | -1.17M | 14.43M | -1.15M |
| Capital Expenditure | - | -1.42M | -808.00K | -723.00K | -714.00K |
| Free Cash Flow | - | 117.15M | -59.81M | -59.97M | -51.97M |
| Net Change in Cash | - | 15.88M | -15.54M | -4.33M | 20.14M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | 61.5% | -868.3% | -1,231.7% | - |
| Net Margin % | - | 62.2% | -880.7% | -1,087.4% | - |
| ROE % | - | 50.1% | -35.1% | -38.2% | -76.7% |
| ROCE % | - | 47.6% | -33.2% | -41.4% | -60.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MOLN
Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZG02VUxJdk1IQ0tZckExTmsyWEpvc1RRaTYtNi1nVXdNTkYwWUFJUE9LTHRkZnFCVmx4MkZRaVBRVlIxY1pORVdON0FVRS1GOUlvNmtKdzlXaXBNcG1uci1fY1NVS2psQU43cmtERENXcjJEbjFaaGU0TWJPazA0MkNrSXRQTXhIbEMybU…
MOLN|Molecular Partners AG|Price:4.060|Chg%:-0.100 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5yb202ZzllcVlSdXZQUExneXFuaHdCaU1obG5LRHJEa0lVMl94a1RscDRYcTZ1R1dkUFZHUnFCZWlhdjB5ZEtNVVFJcDh6TV9hcnRucFBHQlh6bXlua3NCUVV0SV9Ca25iLWVxZEpB?oc=5" target="_blank">MOLN|Molecular Part…
Molecular Partners (MOLN) Holds Steady Near Support Amid Volatile Biotech Sector - Hedge Fund Favorites - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUXhGUGZ6dnZwVjAzSzJFN0lyVkVPX2QxMGVZbDZGRGhiN2REeWVfQ3RVcTBSdkYtNVVoaXBwYnNVNEF6Y1k4elFSSHBDQ0NuNnFuUWRwM0pnWFl1c1Z4M1pfNXRydHM4ZUdOTWhCcDBzUTZFOEEtSDh0NXJPTGluVGNzRDdnQnlGMy1UY0…
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress - Investing.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOUFNlOUljM2xSUnh4MGJQRUd5WEx4d1RGXzFNT1ZHXzRGTWVSWUE3NGhETjI1TEJ1THFXTDQ4dUpwS1pmeWtJXzRaS1o5eXJIRkoycW1iSHRlLTVneUthTnFfdnFFRHJwYU96SERwbkE4YVdzMk1EOW9qRkNreWlrMko5d013Yk9CV3MyMj…
Molecular Partners (NASDAQ: MOLN) begins MP0317 Phase 2 TACTIC study - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYWNKcFhYdW43NjBVYTR4VTBORWhraGVzckNncTJOT3p4b21BUDZFSDJfNndTdTBLZVM0cE9EellOV19ScGhTNkJiYVlrb2lWaFgzaVZGMFNRQnRoaHRxM3JHNTJ1cTVJUXRXUlFxaXBTZlJud0tvZDdYSVRwVTlsSnhoTGV0S1NnbE8yUz…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Molecular Partners (MOLN) and Exelixis (EXEL) - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMiqAJBVV95cUxPd0RxZmJ0dE1pMVZDTVFuTFdmYkpubGdhaXdDb050eG15ZWtFdURxWWNteXRYT2drMllkQUktVEdGM1gtZXZlVGF3Q3JhajlEaExXMkxmblNuaE00Z2paSVV2ZjdHa2R3WFcweEZUOVdTM21XaUo3YldqN3hZeDFIOGdtc1dDNkg1OWxJc0…
MOLN — Frequently Asked Questions
What is the current share price of MOLN?
As of 2026-08-05 17:25 PDT, MOLN trades at $4.16 on NASDAQ/NYSE. Its 52-week range is $3.47 to $5.12.
What is the market capitalisation of MOLN?
MOLN has a market capitalisation of $167.96M on NASDAQ/NYSE.
What is the P/E ratio of MOLN?
MOLN trades at a trailing price-to-earnings (P/E) ratio of -2.52. Its price-to-book (P/B) ratio is 2.09.
What is the return on equity (ROE) of MOLN?
MOLN has a return on equity (ROE) of -76.74%. Its return on capital employed (ROCE) is -60.87%.
Is MOLN a good stock to buy?
This page provides a data-driven analysis of MOLN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.